We're excited to share that our CEO, Segolene Martin, recently had the honor of being featured in the March issue of BECI magazine, Brussels Business. In a two-page interview with Julien Semninckx, Segolene discussed several important topics related to Kantify, the company she founded.

During the interview, Segolene shared her vision for Kantify and why she was inspired to start the company. She also discussed the company's focus on using artificial intelligence for drug discovery and the many benefits this approach can offer.

One of the key areas of discussion was the business case for AI in drug discovery. Segolene explained how AI can help accelerate the discovery of new drugs and improve the efficiency of the drug development process. She also discussed how Kantify is leveraging AI to help pharma and biotech companies identify promising drug candidates more quickly and cost-effectively.

Of course, no discussion of Kantify would be complete without talking about the team behind the company. Segolene shared some insights into the talented group of individuals who make up the Kantify team and their collective passion for using AI to solve some of the world's most pressing problems.

Throughout the interview, Segolene emphasized the values that guide Kantify's work, including a commitment to ethical and responsible use of AI. She also shared her ambitious goals for the company, including expanding into new areas of AI and making a positive impact on society.

We're thrilled that Segolene had the opportunity to share her insights and experiences with the readers of BECI magazine, and we're excited to continue our work at Kantify, using AI to drive positive change in the world.